NCT00004052View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Leukemia
Interventions
BIOLOGICAL

QS21

BIOLOGICAL

bcr-abl peptide vaccine

Trial Locations (2)

10021

Memorial Sloan-Kettering Cancer Center, New York

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00004052 - Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter